Defying analyst expectations, Eisai launches study of a-beta drug BAN 2401 in Alzheimer’s
After Thursday's halt to aducanumab's development dealt a significant blow to the amyloid beta hypothesis in Alzheimer's, analysts had expected BAN 2401 - developed under a partnership with Biogen - to be shelved as well.